Better medicines for every child: GAP-f partners accelerate action on World Children’s Day

On World Children’s Day, the Global Accelerator for Paediatric Formulations Network (GAP-f) recognizes the progress being made towards ensuring that children benefit from medicines that are safe, effective and appropriate for their needs.

Across the global health community, partners are working together to strengthen clinical research, advance the development of paediatric formulations and accelerate access to medicines. Yet, important gaps remain. Turning scientific advances and promising innovations into treatments that reach children, wherever they live, requires sustained investment, stronger collaboration and continued action.

Children should not have to wait for medicines that are designed for their needs. By aligning global priorities, strengthening clinical research and supporting countries to translate innovation into access, we can accelerate progress towards a future where every child has access to the medicines they need.

Dr Sylvie Briand / Chief Scientist & Assistant Director General a.i. Health Systems, Access and Data, World Health Organization

GAP-f’s Strategic Roadmap 2025–2030 provides a shared direction for this work. Through its 30 by ’30 commitment, the network is working to assess priorities across 10 high-burden diseases, accelerate 10 priority medicines and strengthen paediatric medicines ecosystems in 10 countries by 2030.

Progress is being made, but there is more to do. On this World Children’s Day, we reaffirm our commitment to bringing partners together, turning priorities into action and ensuring that advances in medicine translate into better health outcomes for every child.

Prioritizing the medicines children need most

Through WHO’s Paediatric Drug Optimization (PADO) process, GAP-f brings together experts and partners to identify priority medicines and formulations that address critical gaps in prevention and treatment for children. Prioritization exercises across disease areas help align research and investment around shared needs.

A dedicated GAP-f product portfolio will bring these priorities together, helping researchers, product developers and funders focus efforts on the medicines that matter most for children.

Generating better evidence through stronger clinical research

Appropriate medicines require robust evidence on their safety, efficacy and use in children. GAP-f works with partners to enable and strengthen paediatric clinical research, map clinical research site capacity, promote the inclusion of children in clinical studies and support more efficient study designs.

Through a package of clinical research resources , GAP-f will provide the tools to map, strengthen and optimize the clinical research ecosystem for development and evaluation of novel paediatric medicines and formulations. This package brings together information on global paediatric clinical trial sites, paediatric clinical trial design and implementation learning resources, and cross-stakeholder recommendations on optimal study design to support better-coordinated research and accelerate evidence generation for priority medicines.

Accelerating country access and uptake

Developing a suitable medicine is only part of the solution; children must also be able to access it. GAP-f works with WHO technical departments, Member States and partners to identify barriers to access and support the uptake of age-appropriate medicines.

In May 2026, WHO and its GAP-f partners convened a regional workshop on strengthening paediatric medicines ecosystems in the South- East Asia region, bringing together stakeholders from four pilot countries to identify key challenges and practical solutions. A new report from the workshop captures the findings and outlines opportunities to strengthen national paediatric medicines ecosystems, helping countries translate global priorities and evidence into context-specific action.

By connecting global priorities with national needs and health-system realities, GAP-f aims to help countries turn innovation into improved access to appropriate medicines for children.

Working together for every child

Closing the paediatric medicines gap requires sustained collaboration among governments, researchers, product developers, regulators, funders and civil society. As a WHO-hosted network, GAP-f provides a platform to align priorities, strengthen partnerships and accelerate progress across the medicines lifecycle.

On this World Children’s Day, GAP-f calls for continued action to ensure that every child can benefit from appropriate, quality and affordable medicines.

About GAP-f

The Global Accelerator for Paediatric Formulations Network (GAP-f) is a WHO-hosted network bringing together partners across industry, academia, civil society and global health institutions to accelerate the development and uptake of optimal medicines for children.

/Public Release. View in full here.